Antrin; Lu texaphyrin; Lu-Tex; Lutetium texaphyrin; Lutrin; Optrin; PCI 0123
|Jmol 3D model||Interactive image|
|Molar mass||1,166.14 g·mol−1|
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|what is ?)(|
Motexafin lutetium is a texaphyrin, marketed as Antrin by Pharmacyclics Inc.
It is a photosensitiser for use in photodynamic therapy to treat skin conditions and superficial cancers.
It is photoactivated by 732 nm light which allows greater depth of penetration.
Phase II clinical trials were in progress in 1999.
- Pharmacyclics Announces Final Phase 1 Results of Antrin Phototherapy For Coronary Artery Disease, 2002
- http://findarticles.com/p/articles/mi_qa3931/is_200909/ai_n42040200/pg_9/ Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy Photochemistry and Photobiology, Sep/Oct 2009. by O'Connor, Aisling E, Gallagher, William M, Byrne, Annette T
- Antrin Photoangioplasty Phase II Clinical Trial Patient Treated During Live Case Demonstration at TCT, 1999
- Patel, H; Mick, R; Finlay, J; Zhu, TC; Rickter, E; Cengel, KA; Malkowicz, SB; Hahn, SM; Busch, TM (2008). "Motexafin lutetium-photodynamic therapy of prostate cancer: Short and long term effects on PSA". Clinical Cancer Research 14 (15): 4869–76. doi:10.1158/1078-0432.CCR-08-0317. PMC 2680073. PMID 18676760.
|This dermatologic drug article is a stub. You can help Wikipedia by expanding it.|